Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.68 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.59 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.59 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702428 | 0.86 | MEN1 (0.66) | KMOMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14697008 | 0.85 | KMO (0.68) | KMOPLOD2PLOD3PLOD1MEN1 | |
| SCHEMBL10154055 | 0.85 | MEN1 (0.64) | KMOMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13701658 | 0.85 | KMO (0.63) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL13702120 | 0.85 | KMO (0.63) | KMOPLOD2PLOD3PLOD1MEN1 | |
| SCHEMBL13702280 | 0.85 | KMO (0.63) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL13247636 | 0.84 | PLOD2 (0.60) | PLOD2PLOD3PLOD1MEN1KMT2A | |
| SCHEMBL13724478 | 0.83 | KMO (0.74) | KMOPLOD2PLOD3PLOD1MEN1 | |
| SCHEMBL10153966 | 0.83 | MAPT (0.64) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL6263784 | 0.82 | KAT6A (0.60) | MEN1KMT2AHTTALDH1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| CN-105246884-A | Urea derivatives useful as kinase inhibitors | RESPIVERT LTD | 2016-01-13 | — | — | CN | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| EP-2134689-A2 | INHIBITORS OF FOCAL ADHESION KINASE | The Scripps Research Institute (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | KMO 838/4885PLOD2 348/4885PLOD3 205/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | KMO 913/4885PLOD2 2466/4885PLOD3 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.